Main : Complementary/Alternative Therapies Archives

February 02, 2009

Expert Food Tips for Chronic Hepatitis C: Part 1

Discover the importance of consuming whey protein and artichokes, and how these and four other key foods can help your liver resist damage from Hepatitis C infection. This is the first installment of this invaluable 2-part article.

By Nicole Cutler, L.Ac.

Although many are convinced of the importance of food in both causing and relieving health problems, a substantial percentage of physicians fail to utilize nutrition for guiding their patients back to wellness. This is unfortunate, especially when their patients have chronic ailments like Hepatitis C. Regardless of the involvement of their doctor or their stage of liver disease, the food eaten by people with Hepatitis C can either make their bodies feel better or worse.

Our fixit fast culture has developed a higher level of comfort with drugs rather than foods; thus food as medicine has been largely neglected. Circa 400 B.C., the father of modern medicine, Hippocrates, said: “Let your food be your medicine and your medicine, your food.” In the eighteenth century, one of the greatest gastronomes of the world, Jean Anthelme Brillat-Savarin proclaimed: “Tell me what you eat, and I will tell you what you are.” Still popular today, Brillat-Savarin's The Physiology of Taste is a treatise on the relation between man’s joy and survival with his ability to know and experience the pleasures of taste.

In lieu of continually being advised to avoid foods that assault the liver, many with chronic Hepatitis C are left wondering what they should eat. For a clear understanding of six ideal foods for the liver, the following tips are given:

1. Drink Whey Protein – Add whey protein when making a smoothie because it contains lactoferrin and builds glutathione levels. While glutathione is the main antioxidant found inside liver cells, lactoferrin stimulates the immune system and has a direct antiviral property that hampers the Hepatitis C virus from attacking liver cells.

2. Cook Mung Beans – Used by practitioners of Traditional Chinese Medicine to detoxify poisons in the body, mung beans contain a natural protease inhibitor. High in Vitamin B and C, potassium, magnesium, iron, phosphorous, copper, fiber and protein, mung beans’ ability to help a Hepatitis C-laden liver flush out toxins are worth the effort to find and prepare.

3. Eat Shitake – Shitake Mushrooms contain lentinan, a beta-glucan with powerful effects on hepatitis and many other diseases, including cancer. According to the Sloan Kettering Cancer Center, lentinan is used for cancer, high cholesterol, strengthening the immune system and treating infections. These specialty mushrooms also raise white blood cell counts and increase helper t-cells.

4. Love Artichokes – A member of the milk thistle family that helps control blood sugar levels, artichokes are known to support liver health. This fibrous, green veggie contains cynarin, which promotes the flow of bile from the liver to the gallbladder. This is very important because if the bile is not transported adequately to the gallbladder, the liver has an increased risk of being damaged.

5. Munch on Dandelion Greens – By stimulating the flow of bile, dandelion helps both the liver and gallbladder break down fat, prevent gallstones and aid in detoxification. In addition, dandelion greens have mild diuretic properties, which may help relieve ascites, a common consequence of liver cirrhosis.

6. Pick Foods Rich in Selenium – Because Hepatitis C encodes selenoproteins, the virus depletes cells of selenium. Thus, those with Hepatitis C need more selenium than the average person. Researchers hypothesize that when cells are drained of selenium, the Hepatitis C virus will spread from cell to cell looking for more. Thus, supply as much selenium to your cells as possible with the following selenium-rich foods: brazil nuts, broccoli, onions, leeks and garlic.

Using food to guide our health is not a new concept. While awareness of how unhealthy food can damage our bodies has recently grown, much of our medication-oriented society has forgotten about food’s therapeutic potential. Luckily, you needn’t be a certified nutritionist to know what choices to make in the grocery store. By including whey protein, mung beans, shitake mushrooms, artichokes, dandelion greens and selenium-rich foods into your diet, you can help your body feel well despite being infected with Hepatitis C.

References:
http://ayurwhat.blogspot.com/2007/11/mung-beans.html, Mung Beans, Julia Australia, Retrieved January 17, 2009, Ayurwhat?, 2009.

http://www.alchemistlab.com/newsletter11.htm, Top Ten Foods For Treating Chronic Hepatitis, Steven Finkbine, L.Ac., Retrieved January 16, 2009, Alchemist Lab Newsletter # 11, Alchemist Lab, LLC, September 2008.

http://www.allabouthepatitisc.com/readytolearn/living/slowing/eating_
healthy.jsp, Eating Healthy, Schering Corporation, 2009.

http://www.atihealthnet.com/pages/diethiv.html, Diet and Hepatitis C, Retrieved January 16, 2009, AIE Pharmaceuticals, 2009.

http://www.bmj.com/cgi/content/full/328/7433/0-g, “Let Food Be Thy Medicine…”, Richard Smith, Retrieved January 16, 2009, British Medical Journal, January 2004.

http://www.dietblog.com/archives/2007/05/02/10_reasons_to_choose_
food_as_medicine.php, 10 Reasons to Choose Food as Medicine, J. Foster, Retrieved January 16, 2009, Diet-Blog, 2009.

http://www.kitchenproject.com/history/Brillat_Savarin.htm, The Gastronomic Servings of Brillat-Savarin, Amanda Watson Schnetzer, Retrieved January 16, 2009, The Washington Times, July 1999.

http://wwwhealthfreedomcoachcom.blogspot.com/2008/03/dandelion-herbal
-liver-cleanse-better.html, Dandelion: Herbal Liver Cleanse, Better Digestion, and More!, Ellen Landauer, Retrieved January 17, 2009, Health Freedom Coaching, 2009.

http://www.hepccouncilsa.asn.au/factsheets/lifestyle/herbs/theraputicherbs.html, Herbs – Therapeutic and Toxic, Retrieved January 17, 2009, Hepatitis C Council of SA, 2009.

Posted by Editors at 10:38 AM --- Printer-friendly version

October 27, 2008

Why Meditation May Help Hepatitis C

Evidence indicates that incorporating meditation into your daily routine could prevent a Hepatitis C flare up. This article tells you how it works and what you can do.

by Nicole Cutler, L.Ac.

Most who have emerged from the invincible self-perception of the teen years know that their body is more vulnerable to illness when under stress. Whether evaluating the common cold or cancer, medical researchers have repeatedly confirmed this association. For those managing chronic Hepatitis C, the connection between health and stress takes on monumental significance. There are various ways one can reduce or relieve stress. However, meditation’s ability to prevent liver disease from flaring up makes it a top stress-relieving choice for many with chronic Hepatitis C.

Understanding Stress
Because it is a subjective sensation that differs with each person, stress is difficult to define. Caused by both positive and negative experiences, stress is the body’s way of responding to any kind of demand. When feeling stressed, the body reacts by releasing chemicals into the bloodstream to enhance energy and strength. Designed to prepare for “fight or flight,” the initial result of this chemical release is:

· Faster breathing
· Quickened heart rate
· Muscle tension

The physiological response described above is intended to boost people’s abilities when in physical danger. However, people often have no outlet for the extra energy and strength that was initiated by emotional stressors. Therefore, a person’s first line of defense against emotional stress is convincing the body to relax again. By quieting the mind and purposefully slowing down the breathing rate, meditation helps many people vent the tension in their body and subsequently achieve relaxation.

Meditation for Stress Relief
Eastern medical traditions and philosophies have recognized the health benefits of meditation for thousands of years. Due to its positive effects on relieving stress and consequently improving health, meditation is now widely practiced in the many parts of the Western world.

Meditation can be used for stress relief or as part of a spiritual practice. Either way, meditation is a tool to help quiet the mind while promoting awareness and a sense of well-being. Sometimes described as the practice of mindfulness or living in the present, there are many types of meditation a person can experiment with. Meditation can be self-taught or learned from a teacher, book or recording. While it may be simple to learn, regular meditation requires a commitment to its practice. Advocates claim that when part of a daily routine, meditation enforces health by relieving stress and tension.

Meditation for Hepatitis C
People with chronic viral hepatitis typically experience a flare-up of symptoms following a bout of stress. Various types of research have confirmed the connection between stress and its implication on liver inflammation. Some of the conclusions and physiological reasons supporting meditation for chronic Hepatitis C include:

· Research on hypnotically induced fear and anxiety resulted in a significantly decreased flow of blood through the liver.

· Those with Hepatitis C who were categorized as having a consistently stressed and uptight personality (type 1) were more likely to be associated with severe liver disease than those who had a more relaxed, easy-going personality.

· During stress, natural killer cells multiply in the liver. Natural killer cells can contribute to liver cell death and the worsening of liver disease.

· By monitoring the part of the brain that controls the liver, researchers observed that stress impairs blood flow and may lead to, or trigger, liver damage.

· During periods of stress, the body releases glucocorticoids, which maintain balance in the function of each organ. Mice pre-treated with glucocorticoids were found to have deterioration in their liver function.

· Therapies targeting stress reduction such as hypnosis, acupuncture and meditation can stimulate the vagus nerve, which counters the negative effects of stress on the liver.

All of the interactions between stress and the liver are not completely understood. However, there is an undeniable relationship between unrelieved stress and liver disease progression. While meditation does not offer a cure for Hepatitis C, its ability to relieve stress can reduce the virus’ opportunistic approach for causing liver damage.

References:

http://www.hbvadvocate.org/hepatitis/factsheets_pdf/stress_liver.pdf, The Liver: Stress and the Liver, Alan Franciscus, Retrieved September 22, 2008, Hepatitis C Support Project, 2008.

http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Meditation.pdf, HCV Wellness: Meditation, Lucinda Porter, RN, Retrieved September 22, 2008, Hepatitis C Support Project, 2008.

http://www.hepatitis.va.gov/vahep?page=altmed-03-01, Alternative Therapies – Meditation, Retrieved September 22, 2008, United States Department of Veteran Affairs, 2008.

http://www.hepatitiswa.com.au/HC%20treatment.html, Treatment, Retrieved September 22, 2008, Hepatitis Council of Western Australia, 2008.

http://www.mtstcil.org/skills/stress-definition-1.html, What is Stress?, Retrieved September 25, 2008, Mountain State Centers for Independent Living, 2008.

http://www.stress.org/, Home and Stress Reduction, Stress Relievers, Paul J. Rosch, MD, FACP, Retrieved September 24, 2008, The American Institute of Stress, 2008.

http://www.webmd.com/depression/tc/meditation-topic-overview, Meditation – Topic Overview, Retrieved September 24, 2008, Healthwise, Incorporated, 2008.

Posted by Editors at 03:23 PM --- Printer-friendly version

February 28, 2008

6 Tips for Improving HCV Outlook

As your main environment, make sure that your home serves you best. Six simple feng shui suggestions give people with Hepatitis C some tips for improving the energy flow in their home to benefit their liver's health.

by Nicole Cutler, L.Ac.

Living with the Hepatitis C virus (HCV) just may be one of the biggest challenges many people will ever face. A condition that has a 50 percent chance of being helped by harsh, side-effect-laden medications, countless individuals managing HCV spend their days trying to prevent their illness from progressing into full-blown, irreversible liver disease.

In addition to keeping their viral load low, strengthening the liver is how individuals with HCV live a long and rewarding life. To accomplish this goal, those affected are continually searching for safe, inexpensive, logical ways for maintaining their overall health – especially their liver’s health. While most people seeking solutions for wellness search for items they can put inside their body, the practice of feng shui may accomplish a similar feat by paying heed to that which surrounds our bodies.

Feng Shui
An ancient Chinese art and science used for over 5,000 years to heal, balance and enrich people’s lives, feng shui is the practice of placement and arrangement of space to achieve harmony with the environment. A complex body of knowledge that reveals how humans are connected to their environment, applying feng shui principles may improve various aspects of one’s life, including a person’s health.

Feng shui practitioners aim to determine what environmental causes may be impeding the optimal flow of energy for different areas of an individual’s life, such as health, wealth, family, relationships, career, friends, fame, children and knowledge. The methods for analyzing a space and the cures used to correct any problems can vary from esoteric modalities used for centuries to technological solutions conceived in modern times. A physical location where feng shui has been used to create balance generally transfers positive feelings, enhanced health and prosperous endeavors to its occupants – regardless of their personal beliefs in these methods.

Health
According to the time-honored traditions of feng shui, there are several general locations in a home or workspace that correspond with a person’s health.

· The Center – The decorations and order kept at the center of a home, also referred to as the heart, can impact a person’s overall physical, mental and spiritual health. Our health is the center of our lives; when struggling with an illness, all of the other parts of life seem out of balance.

· The East – Concentrating on the most eastern area of your office, room, home or garden provides a powerful opportunity to activate a space’s impact on health. When using the ba gua, a feng shui map used to identify different areas, the east is always associated with health.

· The Kitchen – The state of a kitchen is believed to directly correlate with the occupant’s state of health. As the primary detoxifying organ in the body, the liver is most affected by the cleanliness of the kitchen.

Feng Shui Tips to Help Liver Health
While cleaning, decorating and rearranging your home may help improve the degree of your health, it is only suggested as an adjunct to therapies discussed with a physician, not as a replacement.

By creating a healthy and vibrant home environment, you have a safe, peaceful and energetically balanced space where your body can let down its day-long protective shield and focus on regenerating and self-healing. Some simple feng shui tips for improving liver health include:

1. De-clutter – Clearing out clutter and replacing it with a clean, organized space allows energy to flow more freely. This is especially important if one of the health areas of your home (the center, the east or the kitchen) is filled with boxes and other junk. Likewise, make sure your refrigerator is clean and cleared of unused or old items. The center of a home must be clean, clutter-free and open in order to prevent stagnant energy from congesting one’s health.

2. Laughter – Known universally to be the best medicine, laughter is ideal for managing a chronic disease like HCV. Add something that tickles your fancy to the center of your space for holding a light-hearted energy for your health.

3. Mind the bathroom – There are many opportunities to flush good health away in the bathroom. Keep bathroom doors closed, toilet lids down and shower curtains pulled closed to prevent life-giving energy from flowing out of your home.

4. Use plants to detoxify – Improving the quality of your indoor air with plants is a well-known feng shui tactic. Especially for those trying to reduce the toxic load on their liver, most indoor plants remove chemicals from the air. Since only healthy, vibrant plants support a person’s health, be certain that your plants are well-cared for and well-suited to your home’s light and climate. Several specific plants that purify the air include peace lily, Boston fern, English ivy, rubber plant and spider plant.

5. Bring in healing elements – Placing a picture or other representation of a medicinal plant or other item symbolizing healing in the eastern area of your home may improve health. For HCV, some examples include hanging a picture of dandelion or milk thistle (herbs known to improve liver health) in the East on an eastern wall.

6. Feng shui your bedroom – Making sure energy flows gently in the bedroom provides an ideal space for your body to regenerate, replenish and heal itself during sleep. Since metal conducts electricity and enhances electromagnetic fields, reduce or eliminate metal objects from your bedroom. In addition, avoid sleeping under beams or a sloped ceiling or with your feet in line with the door.

As a complex mix of art and science, there are many levels addressed in a feng shui evaluation of a home or business. To maximize the way your living space can support your health, you have the option of studying feng shui or consulting with a feng shui expert. While everyone may not believe that these six tips will improve their HCV outlook, most will recognize an improved feeling of well-being after instituting them. Regardless of your personal beliefs about the ancient Chinese art and science of interior design, thinking about optimal energy flow focuses your attention on the most important thing – liver health preservation.

References:

http://fengshui.about.com, Top 10 Air-Purifying Feng Shui Plants To Improve the Feng Shui of Your Space, Rodika Tchi, About.com, Inc., 2008.

http://fengshui.about.com, Feng Shui for your Health, Know Feng Shui.com, 2008.

http://fengshui.about.com, How To Clear Your Clutter with Feng Shui, Rodika Tchi, About.com, Inc., 2008.

http://home.ivillage.com, Improve your Health, Karen Rauch Carter, iVillage, 2008.

www.acufinder.com, Feng Shui for Health and Well Being, Melanie Smith, DOM, AP, Acupuncture Magazine, Winter 2007.

www.care2.com, Improve your Health with Feng Shui, Adapted from The Basics of Feng Shui, Phoenix, Perfect Harmony, 2000.

www.dreamsalivemagazine.com, Feng Shui For Your Health And Vitality, Rodika Tchi, MSc, Dreamsalivemagazine.com and Designing Online, Inc., 2008.

Posted by Editors at 01:57 PM --- Printer-friendly version

November 27, 2007

Invention Offers Sick Livers a Well-Needed Rest

Potentially giving the liver a chance to rest and recover, Scottish scientists are working to perfect their artificial liver machine. Conceptually similar to kidney dialysis, this invention temporarily gives the liver a break from its constant duty of filtering out toxins.

Artificial liver offers sufferers new hope
KATE FOSTER (kfoster@scotlandonsunday.com)
http://news.scotsman.com

SCOTTISH scientists are developing an artificial liver that could save the lives of hundreds of patients by avoiding the need for an organ transplant.

Researchers have created a 'bioartificial' liver using living cells in a machine that can filter blood and take over the functions of the natural organ.

They believe the artificial liver - which works outside the body in a way similar to kidney dialysis - could help patients suffering from acute liver disease such as hepatitis or those who have taken a paracetamol overdose, by giving their own liver the chance to 'rest' and heal itself.

They also say it could give a patient dying from chronic liver failure, such as cirrhosis, valuable extra time while they wait for an organ transplant. The team of University of Strathclyde researchers are at the forefront of the technology in the UK.

They have already created devices that replicate the functions of the liver and are now developing ways to allow the living cells used within the device to thrive better.

Deaths from liver disease are on the increase and researchers are trying to find alternatives to transplantation.

Each year in the UK, liver problems kill about 6,700 people but there are only about 650 transplants. Currently, 231,000 people have hepatitis C, which can lead to liver cancer and liver failure.

Over the past 30 years, deaths from chronic liver disease have increased eightfold in men aged between 35 and 44, and sevenfold in women.

Dr John Gaylor, from the Bioengineering Unit at the University of Strathclyde, has led the team responsible for developing the artificial liver.

He said patients could benefit from the treatment within a decade if sufficient funding is put into the research.

"We are looking at creating a device that would buy time for a patient with acute liver failure where the liver has the potential to regenerate.

"If you can buy time the patient can recover. This includes overdose of paracetamol as an attempted suicide and where they go into liver failure within days or weeks. Hepatitis is another big problem. We were also hoping to use the device as a bridge to transplantation where they have chronic liver failure, such as cirrhosis, and would buy time before transplantation. It is to provide some of the lost functions."

Gaylor and his team used live cells taken from rats' livers and placed them on plates in a specially constructed machine. They coated the inside of the plates with a special protein mixture that allowed them to stick and continue to thrive.

Animal blood was pumped into the bioartificial liver and it was shown to have been detoxified by the cells in a similar way to how the liver normally functions. The scientists then 'spiked' the blood with toxins usually found in the blood of patients suffering from liver disease and found this was successfully removed as well.

Gaylor and his team are now looking at how to make the liver cells work best.

In humans, blood would be taken from the patient directly into the bioartificial liver, allowing their own liver a rest from processing toxins. This could allow the patient's liver to heal itself. The treatment would take a number of weeks or months before the liver was repaired.

A spokeswoman for the British Liver Trust said of the developments: "This sounds particularly positive as there is currently nothing similar out there for liver patients. The benefits could be enormous.

"We would support anything that would benefit patients. Most people do not know they have liver disease until it is too late and the damage is done."

Posted by Editors at 02:56 PM --- Printer-friendly version

November 23, 2007

Phlebotomy Gaining Acceptance as HCV Treatment

Most people associate the removal of blood from their veins with donating to the Red Cross or getting tested for some ailment. However, the removal of blood from someone's body can serve many purposes. Learn how the safe ancient practice of bloodletting, or phlebotomy, has proven therapeutic value, and why it is gaining momentum as a treatment of chronic Hepatitis C.

by Nicole Cutler, L.Ac.

Helping to alleviate a variety of illnesses for over 3,000 years, bloodletting has been practiced in most ancient medicinal cultures. Known in the modern healthcare setting as phlebotomy, the removal of blood from someone’s body can have many applications. In addition to being a diagnostic technique and a method of transferring blood to those who need it, phlebotomy is also used therapeutically. While phlebotomy treatment has targeted different kinds of liver diseases over the years, recent research demonstrates its application in the fight against chronic Hepatitis C.

Why Phlebotomy May Help
Phlebotomy may benefit those with Hepatitis C because it lessens the amount of iron in the bloodstream. Toxic in excessive amounts, too much iron in the body contributes to liver damage. As this mineral’s primary storage site, the liver is most susceptible to iron’s toxicity. Our bodies have a limited ability to eliminate excessive amounts of iron.

Because of the liver damage associated with chronic Hepatitis C, people with the virus often have difficulty excreting even normal amounts of iron from their body. Further, those with chronic Hepatitis C are especially vulnerable because the virus inflicts most of its damage by creating free radicals in the liver. As soon as iron molecules collide with those free radicals, liver cell death is the likely result.

Increasing evidence indicates that iron toxicity plays an important role in the pathogenesis of chronic Hepatitis C. As published in the June 2004 edition of Journal of Gastroenterology, Japanese researchers demonstrated this relationship by examining whether iron removal by repeated phlebotomy improves serum alanine aminotransferase (ALT) levels in patients with chronic Hepatitis C. An enzyme produced in liver cells, ALT leaks into the bloodstream when liver cells are damaged. The results showed that people with chronic Hepatitis C receiving biweekly phlebotomy had improvements in their ALT levels compared with those not receiving phlebotomies.

Recent Evidence
Two studies published in 2007 present compelling evidence to include phlebotomy in modern Hepatitis C treatment protocols:

1. Better Than Diet – Knowing that iron likely plays an important role in the development of Hepatitis C, Japanese researchers examined which technique was best for lowering iron levels – phlebotomy or dietary restriction. As published in the May 2007 edition of Internal Medicine, these researchers conducted a randomized, controlled trial comparing phlebotomy with dietary iron reduction in people with chronic Hepatitis C. They concluded that phlebotomy is superior to dietary iron reduction in reducing liver damage from chronic Hepatitis C.

2. Best With Interferon – As published in the September 2007 edition of Digestive Diseases and Sciences, Michigan scientists analyzed six randomized controlled trials comparing phlebotomy and interferon treatment, to interferon alone, in patients with chronic Hepatitis C. All studies used sustained viral response (SVR) as its endpoint, the continued clearance of the Hepatitis C virus from the blood six months after therapy. Researchers found that SVR was attained in 27 percent of patients in the phlebotomy plus interferon group, compared to 12 percent of patients achieving SVR in the interferon group. Although the six trials had different parameters, the authors concluded that phlebotomy improved a person with chronic Hepatitis C’s chances of attaining SVR when combined with interferon treatment.

Previous Non-Responders
Considering the results of studies using phlebotomy to help Hepatitis C, one can surmise that iron may play a role in the persistence of Hepatitis C infection – particularly in interferon non-responders. By removing some of the blood laden with excessive levels of iron, the currently prescribed medications seem to have a better chance at destroying the Hepatitis C virus the second time around. Theoretically, high dose interferon therapy combined with phlebotomy may be a way for previous non-responders to achieve treatment success. However, only continued research will confirm or deny this proposal.

Hope
Iron reduction therapy holds great promise as an effective treatment for those infected with Hepatitis C. Although phlebotomy alone does not reduce Hepatitis C viral load, it increases the effectiveness of interferon therapy when used either before or during administration of this standard medication.

Whether being considered in combination with interferon therapy or alone as an alternative treatment for individuals who cannot tolerate interferon, removing blood regularly decreases iron levels in the body by reducing the number of iron-rich red blood cells. Universally recognized as an iron reduction therapy leading to improvements in liver enzyme levels, the simplicity and safety of phlebotomy is gaining momentum as a recommended technique for Hepatitis C therapy.

References:

Desai TK, et al., Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials, Digestive Diseases and Sciences, September 2007.

Girelli CM, et al., Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload, Recenti Progressi in Medicina, May 1998.

http://health.yahoo.com, Phlebotomy, Nancy Bateman, Yahoo Inc., 2007.

Sumida Y, et al., Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients, Internal Medicine, May 2007.

www.natap.org, Iron and Hepatitis C, James E. Nelson, PhD and Kris V. Kowdley, MD, Current Hepatitis Reports, November 2004.

www.pbs.org, A Brief History of Bloodletting, Gilbert R. Seigworth, MD, The Educational Broadcast Association, 2007.

Yano M, et al., A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan, Journal of Gastroenterology, June 2004.

Posted by Editors at 02:27 PM --- Printer-friendly version

November 13, 2007

How to Relieve HCV Symptoms

When you apply pressure to certain points on your body, it is possible to reduce pain and improve your health. Discover how acupressure can be used to relieve some common symptoms associated with Hepatitis C, including liver-area pain and fatigue.

by Nicole Cutler, L.Ac.

In martial arts, the secret to defeating an opponent who is larger and stronger than you lies with the knowledge and use of pressure points. The different ways to define a pressure point can widely vary, depending on the frame of reference. Regardless of these variations, pressure points are generally understood to be locations on the body that have a large impact on the recipient when pressed firmly. Although many disciplines of combat and self-defense use pressure points to cause discomfort, there are also points on the body capable of relieving discomfort. For people living with the Hepatitis C virus (HCV), there are a handful of pressure points that can be used for the latter purpose. Applying force to specific locations on the body can relieve some of the symptoms characteristic of this illness and ease the side effects known to accompany HCV anti-viral therapy.

Acupressure
Originating from Chinese medical theory, using finger pressure on points on the body to improve health is known as acupressure. Beginning five thousand years ago, Chinese people began using acupressure to improve the flow of energy within the body. By analyzing human pathology, the founders of Chinese medical theory discovered that certain locations on the body contained pools of energy close to the skin’s surface. These spots provided easy access for influencing the body’s energy. Additionally, these medical philosophers understood that blockages in the flow of energy led to imbalances that could result in illness. To regain and maintain health, acupressure is used to help keep energy flowing smoothly, thus encouraging the body towards balance.

Daily stress, muscular tension and illness create energetic imbalances that accumulate over time. Applying pressure to one of over 300 acupressure points can restore balance by improving the localized flow of blood and energy. This influx of circulation allows for nutrients to better reach and feed starved cells as well as increases the body’s efficacy of toxin removal. Additionally, studies show that stimulating specific pressure points reduces stress hormones and increases endorphins, the body’s natural pain-relieving and mood-enhancing chemicals.

How Much Pressure?
When experimenting with acupressure, many people wonder how much force they should use. According to Michael Reed Gach, author of Acupressure’s Potent Points and founder of the Acupressure Institute in Berkeley, California, “the amount of pressure should make the point ‘hurt good,’ somewhere between pain and pleasure.” Use prolonged finger pressure directly on the point – gradual, steady, penetrating pressure for approximately three minutes is ideal. Each point will feel somewhat different when pressed, with some feeling tense, while others feeling sore or achy. For best results, acupressure practitioners advocate relaxing and breathing deeply to further facilitate energy circulation.

Hepatitis C Applications
For some people living with chronic Hepatitis C, finding medication-free techniques to reduce this illness’ symptoms can be more valuable than any amount of money. Whether due to this virus’ strain on the liver or as a result of treatment aimed at squelching HCV, many of the complaints typically associated with Hepatitis C can be relieved by applying pressure to the right point on the body. Acupressure is known to improve energy level, build the immune system, support the liver, relieve nausea, alleviate headaches, enhance mental clarity, ease depression and reduce pain. Below are five pressure points deemed most useful for managing symptoms characteristic of HCV:

1. Nausea – Called Pericardium 6, this point is located on the forearm between the two main tendons, approximately one and a half to two inches above the wrist. This point is usually tender.

2. Fatigue – Called Stomach 36, this point is located on the outer part of the lower leg, in the tender area approximately one and a half to two inches below the knee, just one finger breadth to the outside of the bone. This point also strengthens the immune system.

3. Stress and liver-area pain – Called Liver 3, this point is located on the top of the foot, in the tender spot approximately one to one and a half inches above the toe web of the big toe and second toe.

4. Headaches – Called Large Intestine 4, this point is located on the top part of the hand, between the web of the thumb and index finger. Usually tender, Large Intestine 4 is at the highest point on the bulge formed when the thumb is next to the index finger.

5. Mental confusion and fatigue – Called Governing Vessel 20, this point is on the very top of the head. It is located at the intersection of the following two imaginary lines – (1) from the top point of the ear across to the top point of the other ear and (2) between the eyebrows back over the head to center of the spine.

Although the relief you are seeking may not be immediate, the daily, repeated application of pressure to a point over the course of a few weeks will often shift someone’s physical discomfort. When applying pressure to a point, you may find it possible to gradually work up to holding points for longer periods of time. However, limit yourself to ten minutes per point to avoid the complications of increasing circulation too much. Additionally, a person who is pregnant or severely ill should consult with their doctor prior to adding anything new to their daily routine.

You don’t need to have a black belt in karate to capitalize on the ancient wisdom of the body’s pressure points. Armed with knowing the location and purpose of the preceding five acupressure points, you can reduce your HCV symptoms without putting anything else in your medicine cabinet.

References:

Kallen, Ben, Acupressure for the active guy: this ancient healing art can boost your energy and relieve you pain—without needles, Men’s Fitness, September 2001.

www.acupressure.com, Glossary, Michael Reed Gach, PhD & Bantam Books, 2007.

www.acupressure.com, How to Apply Pressure, Michael Reed Gach, PhD & Bantam Books, 2007.

www.docmisha.com, Applying Chinese Medicine, Misha Ruth Cohen, 2007.

www.fightingarts.com, Pressure Points 1: Going to the Heart Of Pressure Points - What They Really Are, Bruce Everett Miller, PA-C, FightingArts.com, 2007.

www.hcvadvocate.org, Self-Help Acupressure for Hepatitis C, Ramona Draeger, Balancing Touch, Hepatitis C Support Project, 2007.

Posted by Editors at 10:14 AM --- Printer-friendly version

September 18, 2006

Benefits of Medical Marijuana During HCV Treatment

An unlikely ally has been uncovered for Hepatitis C treatment. Interferon and ribavirin treatment is known to inflict severe side effects resulting in low retention rates. While the link is not yet concrete, medical marijuana appears to reduce those side effects, improving a person's chance of completing treatment.

Study: Pot helps cure hepatitis C

Wednesday, September 13, 2006
Tri-Valley Herald Newspaper
By Josh Richman, STAFF WRITER

Medical marijuana users are more likely to finish hepatitis C treatment and so are more likely to be cured, according to a newly published study conducted in San Francisco and Oakland.

Other studies have shown marijuana relieves symptoms, but medical marijuana advocates said this could be the first to show improved cure rates for a life-threatening illness.

The study is by researchers at the University of California, San Francisco, and the Oakland-based Organization to Achieve Solutions in Substance Abuse (OASIS). It was published in the European Journal of Gastroenterology and Hepatology. It found marijuana users being treated for HCV three times more likely to have a "sustained virological response," meaning the virus can't be detected six months after treatment ends.

HCV treatment with ribavirin and interferon causes severe side effects, so many patients quit the long regimen too early.

Of 71 HCV patients studied, 21 finished with a sustained
virological response: 12 of the 22 cannabis users and nine of the 49 nonusers.

"(M)odest cannabis use may offer symptomatic and virological benefit to some patients... by helping them maintain adherence to the challenging medication regimen," the study concluded.

Rob Kampia, executive director of the Marijuana Policy Project in Washington, D.C., issued a news release touting this as "a landmark study, showing that medical marijuana can literally save lives. Every day that our government continues punishing the sick for using this medicine is literally a crime against humanity."

Posted by Editors at 05:28 PM --- Printer-friendly version | Comments (0)

June 28, 2006

Clinical Trials for Natural Hepatitis C Remedy Looking Good

What can interferon non-responders do about Hepatitis C? What about people who cannot or will not tolerate the devastating side effects of interferon therapy? Find out about the positive preliminary results from a medical study of a natural Japanese prescription medicine that's available to patients now.

Progressive Alternative Medicine Solution Undergoes Clinical Trials and Holds Promise of Benefiting Millions of Americans with Hepatitis C
Source: HepCare Inc.
Tuesday, May 23

An estimated five million Americans have been infected with Hepatitis C virus (HCV) according to a study published at the Liver Meeting by the American Association for the Study of Liver Diseases (AASLD) in November 2005. Chronic Hepatitis C is associated with significant morbidity (liver cirrhosis and hepatocellular carcinoma) and mortality. Current treatment is based on interferon and ribavirin. However, treatment options are limited for patients who are not candidates for interferon-based therapy, particularly for those who suffer from HCV genotype 1 infection.

Sho-saiko-to (SST), a standardized herbal formula, is under a clinical phase II trial by a leading New York Cancer Research Institute to determine its effect on Hepatitis C patients. The research group has reported the preliminary results of 15 patients at the 2nd Society of Integrative Oncology Conference in San Diego on November 10, 2005. This study is titled "Sho-saiko-to for Patients with Chronic Hepatitis C Who Are Intolerant to or Have Contraindication to Interferon-Based Therapy: A Phase II Study." SST is know to have anti-fibrotic effect by inhibition of lipid peroxidation in hepatocytes and stellate cells in animal studies. It has also been shown to reduce aminotransferase levels and the incidence of hepatocellular carcinoma in hepatitis and liver cirrhosis patients.

According to the design of the clinical trial, 31 patients will receive SST daily for 52 weeks. Fifteen patients have completed the treatment and the preliminary results have been reported. No serious adverse events have been attributed to SST among any patients who enrolled in the trial. Among the 15 patients who completed the study, reductions in alanine aminotransferase (ALT) were observed in 11 patients and aspartate aminotransferase (AST) in 10 patients. In 10 patients, the liver biopsy showed 20% improvement on histological assessment of the liver. This is consistent with the findings by the Japanese researchers for its anti-inflammatory effect. More interestingly, the majority of the patients whom participated in the clinical trial were genotype 1 infection.

For more information about the herbal remedy, Sho-saiko-to, visit www.shosaikoto.com.

Posted by Editors at 09:16 AM --- Printer-friendly version | Comments (0)

April 18, 2006

Milk Thistle Extract and Its Effect on Liver Fibrosis

A commonly prescribed medicinal plant, milk thistle's protective properties to the liver have been supported by literally hundreds of research studies around the world. A recent article discusses one such study involving the milk thistle extract, Silybin Phytosome®, and its ability to prevent hardening of the liver, a sign of advancing liver disease.

Silybin Phytosome® to Prevent Fibrosis
April 10, 2006
Liversupport.com
Nicole Cutler, L.Ac.

Regardless of its cause, the progression of liver disease is typically measured by the suppleness, and in turn, the functionality of the liver. Recent studies demonstrate the ability of the milk thistle extract, Silybin Phytosome®, to inhibit the hardening of liver tissue.

Some types of liver disease respond well to prescribed therapy, while others take on a chronic status. In addition to addressing the underlying cause of dysfunction, these chronic liver diseases require vigilance to support liver tissue health. While each disease has a preferred conventional treatment standard, an increasing number of clinicians are predominantly concerned with fibrosis prevention.

According to the Merck Manual, Fibrosis is an accumulation of fibrous tissue in the liver resulting from an imbalance between production and degradation of the extracellular matrix, and accentuated by the collapse and condensation of preexisting fibers. In more general terms, fibrosis is the hardening of liver tissue, occurring when the liver is impaired and thus, unable to break down fibrous material.

The liver is touted as the most dynamic organ in the body. This title is not only a result of the numerous functions for which it is responsible, but also for its self-restorative capability. The liver is the only organ capable of regenerating parts of itself to repair any sustained damage.

Helping maintain the liver’s texture is akin to supporting this organ’s health. To prevent or inhibit fibrosis, all individuals with liver disease would benefit from an accelerated regeneration of damaged liver tissue.

In Europe, silymarin, the purified extract of the fruits of S. marianum, and its main constituent, silybin, are used to maintain liver health. Worldwide, milk thistle is, deservedly, one of the most commonly prescribed medicinal plants.

S. marianum is a medicinal plant which has been widely used in traditional European medicine for centuries. Commonly known as milk thistle, St. Mary’s thistle and lady’s thistle, it is native to southern Europe, southern Russia, Asia Minor and North Africa. It has been naturalized to North and South America.

Literally hundreds of research studies, mostly conducted in Europe, have confirmed the remarkable ability of milk thistle to protect the liver against virtually all types of damage: from accidental exposure to chemical pollutants, toxic side effects of medications and even the self-inflicted damage from overindulgence of rich food and alcohol.

The United States National Library of Medicine has catalogued more than 300 scientific studies of milk thistle and its active compounds in their medicine database.

The active ingredients of milk thistle are not very bioavailable, especially in their purified or standardized forms. This means one would need to ingest large amounts to experience beneficial effects. Not only impractical, it could be quite expensive.

A recent study published in Digestive and Liver Disease, clearly demonstrates the ability of Silybin Phytosome® to inhibit liver fibrosis. This study confirmed Silybin Phytosome’s® hepatoprotective abilities by proving it counteracts the progression of liver fibrosis typically seen in chronic liver diseases.

On a molecular level, fibrosis is marked by excessive accumulation of extracellular matrix with collagen. The hepatic stellate cells activate this cumulus. In the referenced study, Silybin Phytosome® reduced hepatic stellate cell activation and proliferation. It also significantly reduced the synthesis and deposition of collagen in liver tissue. The authors of this study concluded that Silybin Phytosome® could inhibit liver fibrosis by reducing the synthesis of collagen and by interfering with excessive accumulation of extracellular material.

Additional evidence of silybin’s value in preventing fibrosis is garnered from a 1984 study demonstrating that silybin accelerates the rate of protein synthesis in the liver, leading to faster cell regeneration. A 1997 German study also reported results where silybin reduced the proliferation of hepatic stellate cells by 50 to 75 percent, which again, is highly indicative of its anti-fibrotic effect.

By their very nature, chronic liver diseases are persistent and stubborn to known modern treatments. Chronic liver disease summons our attention to provide every bit of hepatic support possible, until our medical expertise can catch up with us and ameliorate the offending disease. Years of research point to the ability of Silybin Phytosome® to meet this demand, by preventing the damage that liver diseases typically cause.

For more information on supplements containing Silybin Phytosome®, visit LiverSupport.com.

Posted by Editors at 03:33 PM --- Printer-friendly version | Comments (0)

March 28, 2006

Herbal Components are Beneficial in Treating Cirrhosis

An Iranian research study recently concluded that the herbal components of Liv.52 are beneficial in the treatment of cirrhotic patients. The six-month study demonstrated that patients treated with Liv.52 showed better test results than those treated with placebo.

The efficacy of Liv.52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach.
15 September 2005

Cirrhosis is the irreversible sequel of various disorders that damage liver cells permanently over time. Presently, the use of herbal medicines for prevention and control of chronic liver diseases is in the focus of attention for both the physicians and the patients; the reasons for such shift toward the use of herbals include the expensive cost of conventional drugs, adverse drug reactions, and their inefficacy. In the present study, the efficacy of herbal medicine Liv-52 (consisting of Mandur basma, Tamarix gallica and herbal extracts of Capparis spinosa, Cichorium intybus, Solanum nigrum, Terminalia arjuna and Achillea millefolium) on liver cirrhosis outcomes was compared with the placebo for 6 months in 36 cirrhotic patients referred to Tehran Hepatic Center. The outcome measures included child-pugh score, ascites, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total billirubin, albumin, prothrombin time, platelet and white blood cells counts. The indices were recorded in all patients before and after 6 months of drug or placebo treatment. The results demonstrated that the patients treated with Liv-52 for 6 months had significantly better child-pugh score, decreased ascites, decreased serum ALT and AST. In placebo administered patients all the clinical parameters recorded at beginning of the study were not significantly different than after 6 months. We conclude that Liv-52 possess hepatoprotective effect in cirrhotic patients. This protective effect of Liv-52 can be attributed to the diuretic, anti-inflammatory, anti-oxidative, and immunomodulating properties of the component herbs.

More information about Liv.52 can be found at http://www.liversupport.com.

Abstract: “The efficacy of Liv.52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach,” H. Fallah Huseini, S.M. Alavian, R. Heshmat, M.R. Heydari and K. Abolmaali, Phytomedicine; 12:9; September 2005 (DOI:10.1016/j.phymed.2004.10.003)

Posted by Editors at 12:35 PM --- Printer-friendly version

February 13, 2006

Vitamins Suggested During Combination Therapy

A Japanese research study demonstrates benefits of Vitamin E and C supplementation during combination therapy. These vitamins appear to protect cells from damage typically incurred from conventional Hepatitis C therapy.

Vitamins E and C May Aid Patients with Hepatitis C on Conventional Treatment

In a study involving 30 patients with chronic hepatitis C who were receiving interferon-alpha-2b (IFN-alpha-2b) and ribavirin combination therapy, daily supplementation with vitamin E (500 mg/day) and vitamin C (750 mg/day) was found to improve the fatty acid composition of mononuclear cells. At baseline, all study subjects were found to have a lower level of EPA (eicosapentaenoic acid) and a higher level of the molar ratio of arachidonic acid to EPA in mononuclear cells, as well as a significant correlation between the molar ratio and the level of serum alanine aminotransferase, as compared with healthy volunteers. After intervention, subjects who did not receive nutritional supplementation (the "non-vitamin group" - 16 subjects) experienced a significant decrease in the EPA levels of mononuclear cells at 4 and 8 weeks into treatment, while subjects who received vitamins E and C daily (the "vitamin group" - 14 subjects) maintained the EPA level of mononuclear cells. Both groups experienced a significant decrease in serum levels of alanine aminotransferase two weeks into the treatment. In addition, the “vitamin group” was found to have increased levels of plasma and red blood cell alpha-tocopherol and plasma ascorbic acid levels. These results suggest that patients with hepatitis C who are undergoing IFN-alpha-2b and ribavirin therapy may benefit from supplementation with the antioxidant vitamins, E and C, through their effect on maintaining the level of EPA in mononuclear cell phospholipids. The authors hypothesize that the efficacy of IFN-alpha-2b and ribavirin therapy might be further improved through oral supplementation with EPA. Further research would be needed to test this hypothesis.

Reference
"Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin," Murakami Y, Nagai A, et al, Nutrition, 2006; 22(2): 114-22. (Address: Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectual University, Okayama, Japan).

Posted by Editors at 03:24 PM --- Printer-friendly version

November 27, 2005

Two Studies Recruiting HCV Patients

Sho-saiko-to is the number one liver remedy in Japan. It has been prescribed to over 1.5 million patients (in Japan, doctors medically prescribe certain natural remedies, just like doctors prescribe pharmaceutical drugs in the U.S.).

Based on the large body of research in Japan, studies are now being conducted by the medical establishment here in the USA with regard to SST and hepatitis C.

Although Sho-saiko-to is considered an herbal supplement (and does not require a prescription in the U.S.) it is being taken seriously enough to warrant medical research.

We have been aware of SST for quite some time now and think highly of the clinical evidence compiled so far. We have also agreed to help Dr. Dan Wen, President of Honso USA (the remedy supplier) to recruit patients for these studies. One is in New York City, the other in San Diego. The details and contact information follow.

Please note, we have nothing to do with enrollment in these trials and are simply passing this information on to you so you can follow up directly with those conducting these studies, if you are interested and able to participate.

Please be sure to read the eligibility criteria in each study and see what criteria they are basing their selections on before contacting them.

If you want more information about Sho-saiko-to, you can go to http://www.sho-saiko-to.com. We provide a more in-depth education about this remedy and the opportunity to purchase the prescription-strength version through that website if you so desire.

Here is the information about the New York trial (along with the request from Dr. Wen for me to get this information out to you).

Hi Ralph,

Thank you very much for agreeing to help spread the word about our New York trial on Hepatitis C. As we have discussed on the phone, our clinical trial at Sloan-Kettering is still enrolling patients. We need help to make the awareness of the trial to patients in New York area and I believe the thousands of hep C patients who are subscribing to your e-newsletter at http://www.hepatitis-central.com would be excited to hear this opportunity. I have also copied this email to Dr. Gary Deng, the Primary Investigator of the trial at Sloan, for his information. The following information about the trial is copied from Sloan-Kettering website at http://www.mskcc.org/mskcc/html/2270.cfm?IRBNO=02-073, from which you can see all eligibility criteria and the contact information.

Sincerely,

Dr. Wen

Phase II Study of Sho-saiko-to in Patients with Chronic Hepatitis C Who Cannot Use Interferon

[Protocol 02-073]

Full Title :

SHO-SAIKO-TO FOR PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO OR HAVE CONTRAINDICATION TO INTERFERON-BASED THERAPY: A PHASE II STUDY

Purpose:

Researchers at Memorial Sloan-Kettering Cancer Center are evaluating a Japanese/Chinese herbal medicine called Sho-saiko-to to see if it can help patients with chronic hepatitis C. Chronic hepatitis C may cause inflammation in the liver, which can lead to scarring called fibrosis. In some patients, chronic hepatitis C may result in cirrhosis (severe scarring of the liver), liver failure, and liver cancer.

Standard treatment for chronic hepatitis C includes a drug called interferon, given with or without another drug called ribavirin. Because interferon has a number of side effects, many patients are unable to take it. There are no other proven treatments for chronic hepatitis C.

Sho-saiko-to is an herbal medicine that has been used for many years in Asia to treat liver disease. There is emerging scientific evidence that Sho-saiko-to may benefit patients with hepatitis. The purpose of this phase II study is to determine whether Sho-saiko-to is effective in treating the liver inflammation and injury caused by chronic hepatitis C in patients who cannot take interferon.

Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:

· Patients who have received interferon and ribavirin less than 6 months ago will need to wait for a period of time before enrolling in the study. The doctor will make the specific recommendations.
· Patients must be at least 18 years old.
For more information and to see if you are eligible for this study, please contact to Cheryl Co at 212-639-8610.

Here is the information on the San Diego study:

Hi Ralph,

As you can see below, the UCSD group has approved you to proceed with the contact information for enrolling new patients at their site for the trial and the website link for detail. Please use the two clinical trial sites for your communication materials to introduce the need from each site (New York and San Diego) for patients to enroll.

Best regards,

Dr. Wen

Hi Fatma,

We have a good connection to Hepatitis Central. They are able to broadcast any hepatitis C related news to a large body of patients (http://www.hepatitis-central.com/mt/). Currently they are preparing a news piece to include information about the enrollment for the SST study in New York. If you like we can include the UCSD trial information you have posted at the webpage http://health.ucsd.edu/ntrials/031532.htm to help you enrolling patients.

Please confirm with me if we can proceed with this initiative.

Regards,

Dr. Wen

Hi Dr. Wen,

The matter was discussed with Dr. Hassanein and we can confirm that you can proceed with linking the website. Also, please note that Lita Petcharaporn will be the coordinator on the study. Her contact information is below:

Lita Petcharaporn
Phone: (619) 543-7218
Fax: (619) 543-6392
E-mail: lpetchar@ucsd.edu

Thank you,

Fatma

Fatma Barakat
Clinical Research Coordinator
UCSD Liver Center
200 West Arbor Drive
San Diego, CA 92103-8707
Phone: (619) 543-5459
Fax: (619) 543-6392
fbarakat@ucsd.edu

CHSD Clinical Research project
Project Number: 031532
Scientific Title:

Safety and Tolerability of Sho-saiko-to (SST) in Patients with Compensated Cirrhosis Due to Chronic HCV Infection, A Double blinded Phase II Trial

Principal Investigator (ie., Lead Researcher):

Tarek Hassanein, MD

Description:

The purpose of this study is to evaluate the safety and tolerability of an investigational drug called Sho-saiko-to (SST) as well as find out more about preventing a type of liver cancer called Hepatocellular Carcinoma (HCC) from occuring in patients who have Chronic Hepatitis C infection and cirrhosis. SST is a Chinese herbal drug mixture of seven different herbs: Bupleurum Root, Pinellia, Ginger, Scutellaria, Jujube, Ginseng and Licorice.
This is an outpatient study.

Eligibility criteria:
Gender: Both males and females are eligible to participate. Minimum age: 18. Hepatitis C Virus and Cirrhosis
Exclusions (conditions which would prevent a volunteer from participating in this study):

Please contact Fatma Barakat

Location:

UCSD Medical Center, Hillcrest

Compensation:

Study drug will be provided at no cost.

For further information about this study, please contact:

Fatma Barakat
Phone: (619) 543-5459

Posted by Ralph at 02:41 PM --- Printer-friendly version | Comments (0)

August 11, 2005

A Drug Treatment Based on Glutathione

Okay. This story is of most interest to me because of the origin of the compound they are studying. Oxidized glutathione.

As you may already know, I believe taking the nutritional supplement NAC is important for HCV patients. The body turns NAC into glutathione. While I am not suggesting this is the same as what the researchers are working on, it does point to NAC as being in the right ballpark with regard to nutritional supplementation.

Novelos Therapeutics Reports Positive Results From Phase 1/2 Lung Cancer Study

NOV-002 Treated Patients Show Improved Objective Tumor Response and Higher Tolerance of Chemotherapy Versus the Control Group

NEWTON, MA -- (MARKET WIRE) -- 08/08/2005 -- Novelos Therapeutics, Inc. (OTC BB: NVLT), a biotechnology company focusing on oxidized glutathione for use in fighting cancer and hepatitis, today announced positive results from a U.S.-based Phase 1/2 randomized clinical study in non-small cell lung cancer (NSCLC).

Forty-four chemotherapy-naive Stage IIIB/IV NSCLC patients (late-stage lung cancer patients who have not received prior chemotherapy) were randomized to one of three groups for six months of treatment:

Group A: NOV-002, administered intravenously (IV) and intramuscularly, in combination with cytotoxic chemotherapy.

Group B: NOV-002, administered IV and subcutaneously (SC), in combination with cytotoxic chemotherapy.

Group C: Cytotoxic chemotherapy alone was administered to this control group.

Based on the study protocol, the intent-to-treat analysis of the best overall objective tumor response (i.e. complete or partial tumor shrinkage) showed that eleven out of sixteen (69%) NOV-002 treated patients in Group B demonstrated greater than 50% tumor shrinkage versus only five out of fifteen (33%) in the control group (C). This difference was statistically significant (p=0.044 in a stratified analysis). Six out of thirteen (46%) patients in Group A demonstrated an objective response.

Further, NOV-002 treated patients better tolerated cytotoxic chemotherapy as evidenced by their ability to receive more cycles of chemotherapy compared to the control group (C). 100% of patients in Group B and 85% in Group A were able to complete four cycles of chemotherapy, while only 50% of control group patients (C) were able to do so. These differences were statistically significant (p=0.004). In addition, NOV-002 was well tolerated in this patient population, adding to NOV-002's already extensive safety database.

"We are very encouraged by such positive results in a relatively small Phase 1/2 study," said Dr. Christopher Pazoles, Vice President of Research & Development of Novelos Therapeutics. "The study revealed statistically significant improvement in a number of important efficacy measures after treatment with NOV-002 in combination with chemotherapy compared to chemotherapy alone. This was particularly evident in the case of patients receiving NOV-002 both intravenously and subcutaneously."

"Achieving these positive results in a U.S.-based Phase 1/2 clinical study is especially meaningful for us, because they provide confirmation of the clinical efficacy and excellent safety demonstrated in Russia where NOV-002 is already approved and marketed as GLUTOXIM®," added Harry Palmin, President and Acting CEO of Novelos Therapeutics. "We look forward to commencing a Phase 2B/3 NSCLC study next year."

Lung cancer is the leading cause of cancer death in the U.S. Lung cancer is expected to be diagnosed in approximately 175,000 people, and be responsible for about 165,000 deaths in 2005. NSCLC accounts for more than 80% of lung cancer. Only about 15% of NSCLC patients are diagnosed early enough to be eligible for surgery. Platinum-based chemotherapy regimens, such as carboplatin and paclitaxel (Taxol)*, are standard first-line treatment for advanced NSCLC patients, since these patients are not eligible for surgery. One-year survival rate for this first-line therapy is typically only 35%, median survival is 8.5 months and an objective tumor response rate is about 21%. *www.cancer.gov

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. (OTC BB: NVLT) was established in 1996 to commercialize two promising oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were developed. NOV-002, marketed in Russia by an unrelated entity under the trade name GLUTOXIM®, has been administered to over 5,000 patients, demonstrating clinical efficacy and excellent safety data. The U.S.-based Phase 1/2 clinical study of NOV-002 for lung cancer has been completed, with positive results. The Company plans to file an IND with the FDA for NOV-205 as a mono-therapy for hepatitis C in 2005.

About the Products

NOV-002, the lead compound, is being developed to treat non-small cell lung cancer (NSCLC). NOV-002 is designed to act as a cytoprotectant and an immunomodulator. When used in combination with chemotherapy, NOV-002 increased the one-year survival rate from 17% to 63% in a Russian study, a result that also represents an 80% improvement above the U.S. 35% current standard of care. A U.S.-based Phase 1/2 clinical study has been completed. NOV-002 treated patients demonstrated improved objective tumor response (defined as greater than 50% tumor shrinkage) and higher tolerance of chemotherapy versus the control group. NOV-002 was well tolerated, thus adding to the compound's already extensive safety data base.

NOV-002 is also being developed to treat refractory (that is, not responsive to chemotherapy) ovarian cancer. Two additional clinical indications, radiation protection and psoriasis, will also be investigated for NOV-002.

NOV-205 is being developed to treat chronic hepatitis C in the U.S. NOV-205 is designed to act as a hepatoprotective agent with immunomodulating and antiviral activity. In Russian clinical studies, when used as mono-therapy for one month in hepatitis B and for two months in hepatitis C, NOV-205 has been shown to greatly reduce or eliminate viral loads and to vastly improve liver function relative to existing drugs on the market.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Posted by Ralph at 01:56 AM --- Printer-friendly version | Comments (2)

May 10, 2005

Milk Thistle Doses Studied Are Too Low

This study of previous studies showed inconclusive results for milk thistle preventing death from liver disease.

However, the researchers conclude that higher doses should be studied because milk thistle is non-toxic and has been seen to protect liver cells in many in vitro studies.

Incidentally, the 140mg studied in the past is clearly sub-standard. Maximum Milk Thistle, taken as recommended, provides 720mg of silybin phytosome which delivers many times more protection to your liver with no negative side effects. Go to http://www.maximummilkthistle.com for more information on protecting your liver with this powerful natural remedy.

STUDIES OF HIGHER DOSES OF MILK THISTLE URGED BY RESEARCHERS

Milk thistle, a widely used alternative medicine, is not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease, according to a systematic review of current evidence.

While some studies found that liver-related mortality may be significantly reduced in patients treated with milk thistle, these findings were not duplicated in the higher quality clinical trials.

However, milk thistle was found safe to us with no serious side effects and with participants perceiving improvement in symptoms — although no more than with placebo.

Dr. Andrea Rambaldi, visiting researcher at the of the Centre for Clinical Intervention Research at Copenhagen University Hospital, led a team that reviewed 13 randomized clinical trials involving 915 patients who were treated with milk thistle or its extracts.

Participants had acute or chronic alcoholic liver cirrhosis, liver fibrosis, hepatitis and/or steatosis, and viral-induced liver disease (hepatitis B and/or hepatitis C). Patients with rarer specific forms of liver disease were excluded.

All the trials compared the efficacy of milk thistle or any milk thistle constituent versus placebo or no intervention in patients with liver disease. “There is no evidence supporting or refuting milk thistle for alcoholic and/or hepatitis B or C virus liver diseases,” the authors found.

The review appears in the most recent issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

According to the Centers for Disease Control and Prevention, 170 million people worldwide are infected with hepatitis C, and 2 billion are infected with hepatitis B. While a vaccine exists to prevent hepatitis B, there is no vaccine for hepatitis C.

Although the virus can be cleared in a handful of patients, many strains are resistant to treatment. Drug therapies that focus on long-term suppression of the virus are expensive, and many patients develop a resistance. The current gold standard treatment, which combines injections of interferon and ribavirin, has serious side effects and is hard for patients to tolerate.

With lack of effective treatment for liver disease, researchers have been looking for alternative therapies that curb symptoms with minimum adverse effects on patients.

Milk thistle and its extracts have been used since the time of ancient Greece for medicinal purposes, are currently widely used in Europe for liver disease, and are readily available in the United States at alternative medicine outlets and outdoor markets.

G. Thomas Strickland, M.D., Ph.D., professor at the University of Maryland School of Medicine, has been studying the role of silymarin, an extract of milk thistle, in preventing complications of chronic hepatitis virus infection. Strickland says that the exact mechanism of action of silymarin is unclear.

A problem with current trials, according to Dr. Strickland, is that the dose of silymarin administered, typically 140 mg three times daily, is too low. “I would certainly double it,” he says, “especially since at the current dose we’re not seeing any improvement in acute viral or chronic hepatitis, and we’ve shown that silymarin is totally safe.”

“The problem is, there is no cure for viral hepatitis except bed rest and diet, and treatments like silymarin are worth pursuing,” Strickland says, calling for more research funding.

“We should consider doing randomized clinical trials with higher doses of silymarin,” Dr. Rambaldi concurs.

According to the National Center for Complementary and Alternative Medicine , a part of the National Institutes of Health, studies in laboratory animals suggest that silymarin may benefit the liver by promoting the growth of certain types of liver cells, demonstrating a protective effect, fighting oxidation (a chemical process that damages cells) and inhibiting inflammation.

In their review, Dr. Rambaldi and colleagues conclude, “Milk thistle could potentially affect alcoholic and/or hepatitis B or C virus liver diseases. Therefore, large-scale randomized clinical trials on milk thistle for alcoholic and/or hepatitis B or C liver diseases versus placebo may be needed.”

Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. The Cochrane Database of Systematic Reviews 2005, Issue 2.

Posted by Ralph at 11:52 AM --- Printer-friendly version | Comments (0)

November 29, 2004

Sho-saiko-to Clinical Study Results for Hepatitis C

The following report concerns a study done with Hepatitis C patients who underwent interferon therapy and are classified "non-responders" to interferon. This means they have no other choices of treatment in the medical mainstream.

The results of this Sho-saiko-to study are only preliminary. This is just the first ten of thirty two patients.

The fact that Memorial Sloan-Kettering Cancer Center is conducting this research is very encouraging. Clearly, they bring quite a bit of scientific credibility to this study.

Anti inflammatory and anti viral activity were clearly suggested by the outcomes.

The fact that two of the ten patients had a statistically relevant improvement in biopsy scores is quite impressive. It was not long ago that doctors considered fibrosis non-reversible unless the underlying cause was removed.

Incidentally, for more information about Sho-saiko-to can be found at here.

Initial Results Reported in Clinical Study of Honso Sho-saiko-to -H09- for Hepatitis C
Sunday November 28, 11:55 pm ET

Data Presented at the First Annual Society of Integrative Oncology Conference New York

PHOENIX--(BUSINESS WIRE)--Nov. 28, 2004--A Japanese herbal product, Sho-saiko-to (H09), is under a clinical phase II trial by Memorial Sloan-Kettering Cancer Center to determine its effect on hepatitis C patients. The preliminary results of the trial have been reported at the 1st Annual Society of Integrative Oncology Conference in New York on Nov. 18, 2004. The testing herbal product, Honso® Sho-saiko-to (H09), is manufactured and supplied by Honso Pharmaceutical Co. Ltd., headquartered in Nagoya, Japan, and branched in Phoenix.

Chronic hepatitis C is associated with significant morbidity (liver cirrhosis and hepatocellular carcinoma) and mortality. Current treatment is based on interferon and ribavirin. However, treatment options are limited for patients who are not candidates for interferon-based therapy. This study is titled "Sho-saiko-to for Patients with Chronic Hepatitis C Who Are Intolerant to Or Have Contraindication to Interferon-Based Therapy: A Phase II Study."

Sho-saiko-to has been demonstrated in anti-fibrotic effect by inhibition of lipid peroxidation in hepatocytes and stellate cells in animal studies. It has also been shown to reduce aminotransferase levels and the incidence of hepatocellular carcinoma in hepatitis and liver cirrhosis patients.

According to the design of the clinical trial, a total of 31 patients will receive Sho-saiko-to (H09) granules at 2.5 grams three times daily for 52 weeks.

Ten patients have already completed the treatment and the preliminary results have been reported. No serious adverse events have been attributed to Sho-saiko-to (H09) among all patients who enrolled in the trial.

Among the 10 patients who completed the study, reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed in eight patients, and reduction of viral load was observed in four out of seven detectable patients. This suggests anti-inflammatory and anti-viral activity.

Liver biopsy response is defined as decrease in Knodell score of 2 points or more after the treatment in a blind fashion by an expert pathologist. The histologic responses were observed in two of the 10 patients who completed the study. This suggests anti-fibrotic effect in chronic hepatitis C patients.

Japanese herbal medicine also known as Kampo is part of the East Asian Chinese medicine tradition. Kampo is fundamentally a clinical system based on the classical medical literature dating back to the Han Dynasty in ancient China. In Japan today, fully 75% of physicians use at least some of the traditional Kampo formulas. In the United States, full strength Sho-saiko-to (H09) is available in granules or a lesser strength formula can be found in tablet form as Liver Kampo to consumers.

Posted by Ralph at 01:24 PM --- Printer-friendly version | Comments (0)

November 17, 2004

Complementary Treatment Usage Among Hepatitis C Patients

 

The following article is about a survey presented at the American Association for the Study of Liver Diseases(AASLD) conference.

The survey found that nearly 60% of Hepatitis C patients use Alternative and or Complementary Therapies. Given the low success rate and high level of side effects with current accepted medical therapy, this result should not be surprising.

Also, more doctors are learning about and appreciating the beneficial effects of natural therapies for liver support and protection. Especially milk thistle. This is why Maximum Milk Thistle is still our number one recommendation for people with liver concerns.

 

Complementary and Alternative Treatments: A Survey of People Living with Hepatitis C

The objective of the present study was to provide quantitative measures of the prevalence, patterns, reasons for use and perceived benefits from complementary therapies (CAM) among individuals with hepatitis C (HCV).

A self-administered questionnaire was given to 300 HCV patients attending a community-based outpatient clinic at Vancouver Hospital. The questionnaire included 19 questions regarding demographics, conventional treatments received, specific CAM therapies used, reasons for use, perceived benefit, disclosure to physician and utilization of CAM information resources.

Data was entered into SPSS 10.0 and analyzed primarily for descriptives including frequencies and summary measures.

Users of CAM and non-users were compared by demographics (age, gender, marital status, education, employment status and ethnicity) and medical (time since diagnosis, type of conventional treatment) characteristics.

Contingency analysis between CAM use and potential determinants was performed to select variables to be included in modeling. A multiple logistic regression analysis including all the significant independent variables was then conducted to determine the strongest independent predictors of CAM use.

Results

Fifty-nine percent of patients used CAM therapies with the most common being the herbal supplement milk thistle, exercise, and multivitamins.

The most common reasons given for choosing to use CAM therapies were to

(1) Improve quality of life,

(2) Boost the immune system, and

(3) Slow disease progression.

Most patients felt that CAM therapies had improved their energy levels, reduced stress, and gave them a sense of control over the illness whereas only 43.9% felt that CAM therapies improved liver function.

The majority of those using CAM (81%) had told their physician(s) about their CAM use, but few utilized either their family physician (15%) or their specialist (7%) as sources of CAM information.

CAM users most commonly consulted friends or family (39%) for information about CAM.

CAM users were more likely than nonusers to delay or decline conventional treatment.

Respondents who had never used CAM had typically never thought about it or did not have enough information about the treatments.

Conclusions

Based on their study results, the authors conclude, “More than one half of recently diagnosed HCV patients utilize some form of CAM therapy, and the majority, disclose their use to their physician(s). However, they tend to rely on anecdotal information for their CAM decision-making.

“Dissemination of reliable CAM information is one key to helping patients navigate this difficult arena.

11/08/04
Reference
A L Mulkins and others. COMPLEMENTARY AND ALTERNATIVE MEDICINE: A SURVEY FOR PEOPLE DIAGNOSED WITH HEPATITIS C. Abstract 418 (poster). 55th AASLD. October 29-November 2, 2004. Boston, MA.

Posted by Ralph at 01:36 PM --- Printer-friendly version | Comments (0)